Article
Cell Biology
Hao Hu, Kailiang Zhao, Debao Fang, Zhongyu Wang, Ning Yu, Bo Yao, Kaiyue Liu, Fang Wang, Yide Mei
Summary: The RNA binding protein RALY functions as an oncogenic factor in lung cancer by stabilizing Mdm2 and enhancing its E3 ligase activity toward p53. This leads to increased ubiquitination and degradation of p53, promoting lung tumorigenesis.
Article
Biochemistry & Molecular Biology
Chrisanta Harakandi, Lauraine Nininahazwe, Haiwei Xu, Bingrui Liu, Chenghua He, Yi-Chao Zheng, Hang Zhang
Summary: The USP7-MDM2-p53 network plays a crucial role in regulating p53 and cancer development, with inhibiting USP7 and MDM2 proteins reactivating the p53 signaling pathway leading to cell cycle arrest and apoptosis.
BIOORGANIC CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Ming Gao, Zijuan Qi, Min Deng, Hongyang Huang, Zhijie Xu, Guijie Guo, Jiajun Jing, Xiaofeng Huang, Ming Xu, Jake A. Kloeber, Sijin Liu, Jinzhou Huang, Zhenkun Lou, Jinxiang Han
Summary: The deubiquitinase USP7 plays a key role in controlling redox homeostasis by promoting HO-1 deubiquitination and stabilization in hepatocytes. USP7 inhibitor might be a potential therapeutic agent for treating HO-1 overexpressed liver cancers.
Review
Biochemistry & Molecular Biology
Gouranga Saha, Srija Roy, Malini Basu, Mrinal K. Ghosh
Summary: During three decades of study, the deubiquitinase USP7 has been recognized as a crucial molecule in cellular physiology, especially in tumorigenesis. It functions in various aspects of cancer development, including proliferation, growth signal regulation, cell death prevention, genome stability, angiogenesis, and metastasis. Targeting USP7 has become an important research focus, with the potential to be an effective substitute for current cancer chemotherapeutics.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Article
Cell Biology
Jin Li, Yibin Dai, Han Ge, Songsong Guo, Wei Zhang, Yanling Wang, Laikui Liu, Jie Cheng, Hongbing Jiang
Summary: USP7 is identified as a deubiquitinase for TAZ in HNSCC, promoting cell proliferation, migration, invasion and tumor growth. Inhibition of USP7 can significantly suppress tumor growth, suggesting that USP7 may serve as a potential therapeutic target for HNSCC.
CELL DEATH & DISEASE
(2022)
Article
Cell Biology
Yu-Ting Huang, An-Chieh Cheng, Hui-Chi Tang, Guo-Cheng Huang, Ling Cai, Ta-Hsien Lin, Kou-Juey Wu, Ping-Hui Tseng, Greg G. Wang, Wei-Yi Chen
Summary: The study reveals that USP7 regulates the autoregulation of SMAD3 in p53-deficient lung cancer, inhibiting cell progression. USP7 mediates SMAD3 de-monoubiquitination, enhancing SMAD3 autoregulation to suppress cancer progression in p53-deficient lung cancer.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Haixia Zhuang, Ying Ren, Chenyu Mao, Yueya Zhong, Zubin Zhang, Biyin Cao, Yuming Zhang, Jinqi Huang, Guoqiang Xu, Zhenqian Huang, Yujia Xu, Xinliang Mao
Summary: The zinc finger ubiquitin ligase RNF6 undergoes auto-ubiquitination mediated by its RING domain, and the process can be prevented by the deubiquitinating enzyme USP7. Anti-cancer drugs can induce polyubiquitination and degradation of RNF6, and reexpression of RNF6 can rescue drug-induced cell apoptosis.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2022)
Article
Biochemistry & Molecular Biology
Lei Shi, Xiangyu Shen, Yuan Shen
Summary: Posttranslational histone modifications play important roles in regulating chromatin structure and transcriptional regulation. Histone H2B deubiquitinase USP49 is involved in HCT116 cell proliferation and regulates cell growth by modulating the MDM2-p53 pathway.
MOLECULAR AND CELLULAR BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xu Li, Tao Wang, Yue Tao, Xiaojun Wang, Limeng Li, Jianjun Liu
Summary: This study reveals that inhibition of USP7 can suppress AGEs-induced cell cycle arrest and cell senescence of HUVECs through promoting p53 ubiquitination, providing a potential treatment strategy for diabetic foot ulcers.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA
(2022)
Article
Biochemistry & Molecular Biology
Jingjie Yi, Huan Li, Bo Chu, Ning Kon, Xiaoping Hu, Jianping Hu, Yan Xiong, H. Umit Kaniskan, Jian Jin, Wei Gu
Summary: The oncoprotein FOXM1 acts as a potential driver for tumor growth in triple-negative breast cancers (TNBC), and USP7 stabilizes FOXM1 through deubiquitination, promoting TNBC cell growth. The USP7 degrader PU7-1 effectively suppresses FOXM1 functions and inhibits TNBC cell growth. These findings reveal the potential therapeutic use of a USP7 degrader for the treatment of TNBC.
CELL DEATH AND DIFFERENTIATION
(2023)
Article
Biochemistry & Molecular Biology
Christophe Le Clorennec, Karen Lee, Yuchen Huo, Peter E. Zage
Summary: USP7 inhibition is a promising therapeutic strategy for high-risk and relapsed neuroblastoma (NB) in children. Inhibiting USP7 activates the p53 pathway, induces apoptosis in NB cells, and reduces N-myc protein levels. The combination of USP7 and MDM2 inhibition shows enhanced efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Xiaoming Xu, Mingchen Wang, Hailong Xu, Na Liu, Kaixian Chen, Cheng Luo, Shijie Chen, Hua Chen
Summary: A series of novel 2-aminopyridine derivatives were synthesized and evaluated for their USP7 inhibitory activities. Compounds 7 and 21 showed significant binding interactions with USP7 according to surface plasmon resonance binding assay.
BIOORGANIC CHEMISTRY
(2022)
Review
Pharmacology & Pharmacy
Lauraine Nininahazwe, Bingrui Liu, Chenghua He, Hang Zhang, Zhe-Sheng Chen
Summary: USP7, as a deubiquitinating enzyme, plays a crucial role in cancer and other diseases, with current research focusing on its role in tumorigenesis, clinical studies, and development of inhibitors. A comprehensive understanding of USP7 could provide insights for drug discovery in various diseases.
DRUG DISCOVERY TODAY
(2021)
Article
Cell Biology
Sanjay Kumar, Paul B. Tchounwou
Summary: This study aimed to investigate the action of cisplatin (CDDP) in acute promyelocytic leukaemia (APL) cells as an alternative treatment for ATO-resistant APL patients. The findings showed that CDDP activated p53 expression in APL cells through stress signals catalysed by ATM and ATR protein kinases, CHK1 and CHK2 phosphorylation, and downregulation and dissociation of the MDM2-DAXX-HAUSP complex. CDDP also stimulated an increased number of promyelocytes with dense granules, activated p53 expression, and downregulated MDM2 in the liver and bone marrow of APL mice. These results highlight a novel mode of action of CDDP targeting p53 expression in APL and may contribute to the development of new anti-leukaemic compounds for the treatment of APL patients.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2022)
Article
Multidisciplinary Sciences
Xiao-Wen Zhang, Na Feng, Yan-Chen Liu, Qiang Guo, Jing-Kang Wang, Yi-Zhen Bai, Xiao-Ming Ye, Zhuo Yang, Heng Yang, Yang Liu, Mi-Mi Yang, Yan-Hang Wang, Xiao-Meng Shi, Dan Liu, Peng-Fei Tu, Ke-Wu Zeng
Summary: This study discovers a natural small molecule called eupalinolide B (EB) that inhibits USP7 to alleviate symptoms of neurodegenerative diseases. EB selectively modifies the Cys(576) site, inhibiting the activity of USP7 and causing the degradation of Keap1. This leads to the activation of anti-neuroinflammation genes in microglia. The effectiveness of this treatment method is validated in mouse models.
Article
Biochemistry & Molecular Biology
Yuri Nagaoka, Kotone Oshiro, Yuta Yoshino, Toshiyuki Matsunaga, Satoshi Endo, Akira Ikari
Summary: This study investigated the effect of intercellular adhesion molecule CLDN1 on the anticancer drug sensitivity of small-cell lung cancer (SCLC) cells. It was found that overexpression of CLDN1 decreased the sensitivity of SCLC cells to anticancer drugs and enhanced their migratory capacity through the activation of the TGF-81/EMT signaling pathway. Treatment with EMT inhibitors showed potential in overcoming the reduced sensitivity to anticancer drugs in CLDN1-overexpressing SCLC cells.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2024)